Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial ECOG 1808

Title
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features
Principal Investigator
Timothy Kuzel
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.ECOG 1808
Purpose
The purpose of this study is to find out what effects, good and/or bad, sunitinib alone or the chemotherapy combination of sunitinib and gemcitabine has on advanced kidney cancer with sarcomatoid features.
Overview
The use of sunitinib alone is approved for the use in advanced renal cell cancer, but using sunitinib and gemcitabine together is investigational and has not been approved by the Food and Drug Administration (FDA) for use in this type of cancer. Gemcitabine has been used for renal cell cancer in the past and is commercially available. It is also approved for pancreatic cancer.
Eligibility
Some of the eligibility criteria include:
  • Participants must be 18 years of age or older.
  • Patients must have renal cell carcinoma (of any subtype) containing any sarcomatoid features.
  • Participants must not have had radiation therapy less than 2 weeks prior to randomization and participants must be recovered from any toxicities associated with radiation therapy.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Participants will be "randomized" into one of the study groups, "arm A" or "arm B". Randomization means that participants will be put into a group by chance. Participants in arm A will receive gemcitabine by vein over 30 minutes on days 1, 8, 22 and 29 of every treatment cycle. A treatment cycle is 42 days. Participants will also receive sunitinib by mouth on days 1 through 14 and days 22 through 35 of each treatment cycle. Participants will have a break from treatment on days 15-21 and days 36-42 of each cycle. Participants in arm B will receive sunitinib by mouth on days 1 through 14 and days 22 through 35 of each treatment cycle. A treatment cycle is 42 days. Participants will have a break from treatment on days 15-21 and days 36-42 of each cycle. Participants in both arms will receive treatment for about a year total, as long as the cancer is responding to treatment and there are no serious side effects.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Timothy Kuzel

last updated: 22-Nov-14 11:45 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.